MIF-Induced Augmentation of Melatonin Functions: Possible Relevance to Mechanisms of Action of MIF-1 in Movement Disorders

References

• Aldegunde M., Miguez I., Veira J. Effects of pinealectomy on regional brain serotonin metabolism. International Journal of Neuroscience 1985; 26: 9–13
   PubMed Web of Science ®Google Scholar
• Anton-Tay F. Pineal-Brain relationships. The pineal gland, G. E. W. Wolstenholme, Knight. Churchill Livingstone, Edinburgh and London 1971; 213–220
   Google Scholar
• Anton-Tay F., Chou C., Anton S., Wurtman R. J. Brain serotonin concentrations: elevation following intraperitoneal administration of melatonin. Science 1968; 162: 277–278
   PubMed Web of Science ®Google Scholar
• Anton-Tay F., Diaz J. L., Fernandez-Guardiola A. On the effect of melatonin upon human brain. Its possible therapeutic implications. Life Sciences 1971; 10: 841–850
   Web of Science ®Google Scholar
• Barbeau A., Roy M., Gonce M., Labreoque L. Newer therapeutic approaches in Parkinson's disease. Advances in neurology, L. J. Poirier, T. L. Sourkes, P. J. Bedard. Raven Press, New York 1978; 433–437
   Google Scholar
• Bradbury A. J., Kelly M. E., Smith J. A. Melatonin action in the mid-brain can regulate forebrain dopamine function both behaviorally and biochemically. The pineal gland: Endocrine aspects, G. M. Brown, S. D. Wainwright. Pergamon Press, Oxford 1985; 327–332
   Google Scholar
• Carman J. S., Post R. M., Buswell R., Goodwin F. K. Negative effects of melatonin on depression. American Journal of Psychiatry 1976; 133: 1181–1186
   PubMed Web of Science ®Google Scholar
• Case T. C., Snider S. R., Hruby V. J., Rockway T. Active and inactive L-Prolyl-L-Leucyl Glycinamide synthetic analogs in rat models of levodopa-treated Parkinson's disease. Life Sciences 1985; 36: 2531–2537
   PubMed Web of Science ®Google Scholar
• Castensson S., Sievertsson H., Lindeke B., Sum C. Y. Studies on the inhibition of oxotremorine induced tremor by a melanocyte-stimulating hormone releasing inhibiting factor, thyrotropin releasing hormone and related peptides. FEBS Letters 1974; 44: 101–105
   PubMed Web of Science ®Google Scholar
• Chiu P., Rajakumar G., Chiu S., Johnson R. L., Mishra R. K. Mesolimbic and striatal dopamine receptor supersensitivity: Prophylactic and reversal effects of L-Prolyl-L-Leucyl-Glycinamide (PLG). Peptides 1985; 6: 179–183
   PubMed Web of Science ®Google Scholar
• Cotzias G. C., Tang L. C., Miller S., Ginos J. Z. Melatonin and abnormal movements induced by L-dopa in mice. Science 1971; 173: 450–452
   PubMed Web of Science ®Google Scholar
• Cotzias G. C., Van Woert M. H., Schiffer L. M. Aromatic amino acids and modification of Parkinsonism. New England Journal of Medicine 1967; 276: 374–379
   PubMed Web of Science ®Google Scholar
• Datta P. C., King M. G. Melatonin: Effects on brain and behavior. Neuroscience & Biobehavioral Reviews 1980; 4: 451–458
   PubMed Web of Science ®Google Scholar
• Davis K. L., Kastin A. J., Beilstein B. A., Vento A. L. MSH and MIF-1 in animal models of Tardive dyskinesia. Pharmacology Biochemistry & Behavior 1980; 13: 37–40
   PubMed Web of Science ®Google Scholar
• Dray A. Serotonin in the basal ganglia. Journal of Physiology (Paris) 1981; 77: 393–403
   PubMedGoogle Scholar
• Ehrensing R. H., Kastin A. J. Melanocyte-stimulating hormone release inhibiting hormones as an antidepressant—A pilot study. Archives of General Psychiatry 1974; 30: 63–65
   PubMed Web of Science ®Google Scholar
• Ehrensing R. H., Kastin A. J., Larsons P. F., Bishop G. A. Melanocyte-stimulating hormone release-inhibiting factor-1 and tardive dyskinesia. Diseases of the Nervous System 1977; 38: 303–307
   PubMedGoogle Scholar
• Fibiger H. C., Lloyd K. G. Neurobiological substrates of tardive dyskinesia: the GABA hypothesis. Trends in Neurosciences 1984; 7: 462–464
   Web of Science ®Google Scholar
• Fischer P. A., Schneider E., Jacobi P., Maxion H. Effect of melanocyte-stimulating hormone-release inhibiting factor (MIF) in Parkinson's syndrome. European Neurology 1974; 12: 360–368
   PubMed Web of Science ®Google Scholar
• Kane J., Woerner M., Lieberman J. Tardive dyskinesia: prevalence, incidence, and risk factors. Journal of Clinical Psychopharmacology 1988; 8(suppl)52S–56S
   PubMed Web of Science ®Google Scholar
• Kastin A. J., Kullander S., Borglin N. E., Dahlberg B., Dysteraas K., Krakau C. E. T., Ingvar D. H., Miller M. C., Bowers C. Y., Schally A. V. Extrapigmentary effects of melanocyte-stimulating hormone in amenorrheic women. Lancet 1968; 1: 1007–1010
   PubMed Web of Science ®Google Scholar
• Kastin A. J., Lawrence S. P., Coy D. H. Radioimmunoassay of MIF-1 Tyr-MIF-1-like material in rat pineal. Pharmacology. Biochemistry & Behavior 1980; 13: 901–905
   PubMed Web of Science ®Google Scholar
• Kastin A. J., Redding T. W., Schally A. V. MSH activity in rat pituitaries after pinealectomy. Proceedings of the Society of Experimental Biology and Medicine 1967; 124: 1275–1277
   PubMed Web of Science ®Google Scholar
• Kastin A. J., Viosca S., Nair R. M. G., Schally A. V., Miller M. C. Interactions between pineal, hypothalamus and pituitary involving melatonin, MSH release-inhibiting factor and MSH. Endocrinology 1972; 91: 1323–1328
   PubMed Web of Science ®Google Scholar
• Kopp N., Clasutrat B., Tappaz M. Evidence for the presence of melatonin in the human brain. Neuroscience Letters 1980; 19: 237–242
   PubMed Web of Science ®Google Scholar
• Lynch H. J., Wang P., Wurtman R. J. Increase in rat pineal melatonin content following L-dopa administration. Life Sciences 1973; 12: 145–151
   Web of Science ®Google Scholar
• Mayeux R., Stern Y., Williams J. B. W., Cote L. J. The relationship of serotonin depression in Parkinson's disease. Movement Disorders 1988; 3: 237–244
   PubMed Web of Science ®Google Scholar
• Miles A., Philbrick D. R. S. Melatonin in psychiatry. Biological Psychiatry 1988; 23: 405–425
   PubMed Web of Science ®Google Scholar
• Narabayashi H., Kondo T., Hayashi A. L-threo-3,4-dihydroxyphenylserine treatment for akinesia and freezing of Parkinsonism. Proceedings of the Japanese Academy 1981; 57: 351–354
   Google Scholar
• O'Donohue T. L., Dorsa D. M. The opiomelanotrophinergic neuronal and endocrine systems. Peptides 1982; 3: 353–395
   PubMed Web of Science ®Google Scholar
• O'Donohue T. L., Miller R. I., Pendleton R. C., Jacobwitz D. M. Demonstration of an endogenous circadian rhythm of alpha-melanocyte stimulating hormone in the rat pineal gland. Brain Research 1980; 186: 145–155
   PubMed Web of Science ®Google Scholar
• Oliver C., Porter J. C. Distribution and characterization of alpha-melanocyte stimulating hormone in the rat brain. Endocrinology 1978; 102: 697–705
   PubMed Web of Science ®Google Scholar
• Pique L., Jegou S., Bertagna X., Javoy-Agid F., Seurin D., Proeschel M. F., Girard F., Agid Y., Vaudry H., Luton J. P. Pro-opiomelanocortin peptides in the human hypothalamus: Comparative studies between normal subjects and Parkinson patients. Neuroscience Letters 1985; 54: 141–146
   PubMed Web of Science ®Google Scholar
• Rainero I., Kaye J. A., May C., Durso R., Katz D. I., Albert M. L., Wolfe N., Pinessi L., Friedland R. P., Rapoport S. I. Alpha-melanocyte-stimulating hormone-like immunoreactivity is increased in cerebrospinal fluid of patients with Parkinson's disease. Archives of Neurology 1988; 45: 1224–1227
   PubMedGoogle Scholar
• Ricaurte G. A., Kopin I., Forno L. S., Delanney L. E., Langston E., Langston J. W. Aging and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced degeneration of dopaminergic neurons in the substantia nigra. Brain Research 1987; 403: 43–51
   PubMed Web of Science ®Google Scholar
• Rosenstein R. E., Cardinali D. P. Melatonin increases in vivo GABA accumulation in rat hypothalamus, cerebellum, cerebral cortex and pineal gland. Brain Research 1986; 398: 403–406
   PubMed Web of Science ®Google Scholar
• Sack R. L., Lewy A. J., Erb D. L., Vollmer W. M., Singer C. M. Human melatonin production decreases with age. Journal of Pineal Research 1986; 3: 379–388
   PubMed Web of Science ®Google Scholar
• Sakai K. K., Schneider D., Felt B., Marks B. H. The effect of alpha-MSH on beta-adrenergic receptor mechanisms in the rat pineal. Life Sciences 1976; 19: 1145–1150
   PubMed Web of Science ®Google Scholar
• Sandyk R. Mechanisms of recovery in MPTP-induced Parkinsonism. Neuroscience 1988; 27: 727–729
   PubMed Web of Science ®Google Scholar
• Sandyk R. Attentuation of reserpine-induced catalepsy by melatonin and the role of the opioid system. International Journal of Neuroscience 1989; 48: 297–301
   PubMed Web of Science ®Google Scholar
• Sandyk R. Pineal melatonin functions: Possible relevance to Parkinson's disease. International Journal of Neuroscience, in press a
   Google Scholar
• Sandyk R. Pineal melatonin functions and the depression of Parkinson's disease. International Journal of Neuroscience, in press b
   Google Scholar
• Sandyk R. Melanocyte-stimulating hormone and persistent Tardive dyskinesia. International Journal of Neuroscience, in press c
   Web of Science ®Google Scholar
• Sandyk R., Fisher H. Serotonin in involuntary movement disorders. International Journal of Neuroscience 1988; 42: 185–205
   PubMed Web of Science ®Google Scholar
• Sandyk R., Fisher H. L-tryptophan supplementation in Parkinson's disease. International Journal of Neuroscience 1989; 45: 215–219
   PubMed Web of Science ®Google Scholar
• Sandyk R., Fisher H. The protective function of the pineal gland in Tardive dyskinesia. International Journal of Neuroscience 1988b; 43: 215–218
   PubMed Web of Science ®Google Scholar
• Sandyk R., Iacono R. P. The relationship of the reticular system to the primary pathoetiology of Parkinson's disease. International Journal of Neuroscience 1989; 42: 297–300
   Web of Science ®Google Scholar
• Sheng J. G., Xu D. L., Yu H. Z., Xu X. R., Tang Q. M. Partial protection from the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) by Pro-Leu-Gly-NH2 (PLG; MIF-1). Life Sciences 1987; 40: 2007–2010
   PubMed Web of Science ®Google Scholar
• Shuster S., Thody A. J., Plummer N., Goolamali S. K., Bates D. Melanocyte-stimulating hormone and Parkinsonism. Lancet 1973; 1: 463–465
   PubMed Web of Science ®Google Scholar
• Souetre E., Salvati E., Belugou J. L., Robert P., Brunet G., Darcourt G. Antidepressant effect of 5-methoxypsoralen: A preliminary report. Psychopharmacology 1988; 95: 430–431
   PubMed Web of Science ®Google Scholar
• Souetre E., Salvati E., Pringuey D., Bruent G., Savelli M., Krebs B., Darcourt G. Rythme circadien de la melatonine dans la depression: Etude transversale et longitudinale. Actual Psychiatriques 1986; 5: 88–93
   Google Scholar
• Taleisnik S., Celis M. E. Control of melanocyte stimulating hormone secretion. Proceedings of the 4th International Congress of Endocrinology (Washington). Excerpta Medica, Amsterdam 1973; 100–106
   Google Scholar
• Torre E., Celis M. E., Chiocchio S. R. Alpha-MSH and Pro-Leu-Gly-NH2 (PLG; MIF-1): Influence on dopamine (DA) uptake in crude synaptosomal preparations from rat mediobasal hypothalamus (MBH) and caudate putamen. Peptides 1984; 5: 669–674
   PubMed Web of Science ®Google Scholar
• Vaughan M. K. Pineal gland peptides: An overview. The pineal gland, R. J. Reiter. Raven Press, New York 1984; 39–81
   Google Scholar
• Wendel O. T., Waterbury L. D., Pearce L. A. Increase in monoamine concentrations in rat brain following melatonin administration. Experientia 1974; 30: 1167–1168
   PubMedGoogle Scholar
• Wetterberg L., Beck-Friis J., Aperia B., Petterson U. Melatonin/cortisol ratio in depression. Lancet 1979; 2: 1361
   Web of Science ®Google Scholar
• Xu D. L., Yu W. C., Pan G. B., Chen S. D. Mechanism of action of L-Leucyl-Glycinamide and its effect on Parkinson's disease. Advances in neurology, M. D. Yahr, K. J. Bergman. Raven Press, New York 1986; 587–590
   Google Scholar